133 related articles for article (PubMed ID: 9484666)
1. Monitoring percent free PSA in serial specimens: improvement of test specificity, early detection, and identification of occult tumors.
Wu JT; Liu GH; Zhang P; Stephenson RA
J Clin Lab Anal; 1998; 12(1):26-31. PubMed ID: 9484666
[TBL] [Abstract][Full Text] [Related]
2. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
[TBL] [Abstract][Full Text] [Related]
3. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
[TBL] [Abstract][Full Text] [Related]
4. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when?
Basso D; Fogar P; Piva MG; Navaglia F; Mazza S; Prayer-Galetti T; Castellucci E; Pagano F; Plebani M
Urology; 2000 May; 55(5):710-5. PubMed ID: 10792086
[TBL] [Abstract][Full Text] [Related]
5. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
6. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
[TBL] [Abstract][Full Text] [Related]
7. Advantages of replacing the total PSA assay with the assay for PSA-alpha 1-antichymotrypsin complex for the screening and management of prostate cancer.
Wu JT; Liu GH
J Clin Lab Anal; 1998; 12(1):32-40. PubMed ID: 9484667
[TBL] [Abstract][Full Text] [Related]
8. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.
Minardi D; Galosi AB; Recchioni A; Giammarco L; Polito M; Muzzonigro G
Urol Int; 2001; 67(4):272-82. PubMed ID: 11741128
[TBL] [Abstract][Full Text] [Related]
10. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
Okegawa T; Noda H; Nutahara K; Higashihara E
Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
[TBL] [Abstract][Full Text] [Related]
12. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer.
Zhang WM; Finne P; Leinonen J; Salo J; Stenman UH
Urology; 2000 Aug; 56(2):267-72. PubMed ID: 10925092
[TBL] [Abstract][Full Text] [Related]
13. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
Gao ZW; Liu G; Sheng BW
Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
[TBL] [Abstract][Full Text] [Related]
14. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
Jung K; Stephan C; Elgeti U; Lein M; Brux B; Kristiansen G; Rudolph B; Hauptmann S; Schnorr D; Loening SA; Sinha P
Int J Cancer; 2001 Sep; 93(5):759-65. PubMed ID: 11477592
[TBL] [Abstract][Full Text] [Related]
15. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma.
Froschermaier SE; Pilarsky CP; Wirth MP
Urology; 1996 Apr; 47(4):525-8. PubMed ID: 8638361
[TBL] [Abstract][Full Text] [Related]
17. The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer.
Kochañska-Dziurowicz AA; Mielniczuk MR; Stojko A; Kaletka J
Br J Urol; 1998 Jun; 81(6):834-8. PubMed ID: 9666767
[TBL] [Abstract][Full Text] [Related]
18. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
Chen ZD; Wei SM; Cai SL
Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
[TBL] [Abstract][Full Text] [Related]
19. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
